Previous studies from this laboratory suggest that the administration of either endotoxin or complement activated plasma to animals in vivo results in activation of prostaglandin biosynthesis with significant hemodynamic consequences and effects on microvascular integrity. The objective of the proposed research is to characterize the relationship between gram negative bacterial endotoxin, the complement system and products of the arachidonic acid cascade. The present studies will be undertaken in three different models representing three levels of physiologic organization. Investigations of 14C arachidonic acid metabolism in isolated liver slice and granulocyte preparations wil characterize the in vitro response of the arachidonic cascade to endotoxin and complement treatment. The pattern and magnitude of both cyclo-oxygenase and lipoxygenase pathways will be characterized. Further studies will be carried out in vitro in an isolated, perfused rabbit liver model to characterize the direct effect of activated complement on cellular prostanoid production. In addition, studies will be undertaken to determine the mechanism of complement activation of the arachidonic acid cascade. These will include studies using calcium influx inhibitors, phospholipase inhibitors and free radical scavangers. In vivo studies will also be carried out in a rabbit model to establish the sequence of physiologic events related to endotoxin induced cellular injury, complement activation, and prostanoid production. Studies will include activation of the complement system with cobra venom factor with concurrent measurement of endogeneous prostanoid production; stimulation of endogenous prostanoid production by substrate supplementation with concurrent assessment of the CH50 complement titer, and endotoxin administration to complement replete and depleted animals with prostanoid quantitation. Results from these in vitro and in vivo studies will characterize the previously unrecognized relationship between endogenous complement activation, prostanoid production and subsequent pathophysiology. This data will be of value in not only understanding the pathophysiology of endotoxic shock, but should also be of value in understanding and managing other complement related disease states such as hemodialysis induced lung injury, Felty's Syndrome, systemic lupus erythematosus and glomerulonephritis.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM028023-07
Application #
3275290
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Project Start
1980-09-01
Project End
1987-08-31
Budget Start
1986-09-01
Budget End
1987-08-31
Support Year
7
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Type
Schools of Medicine
DUNS #
061197161
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Flynn, J T; Westbrooks, M; Lucas, K A (1997) Establishment and characterization of a line of adipose-derived human microvascular endothelial cells (HADMEC-5) transformed by simian virus 40 large T antigen expression: application to endotoxin research. Shock 8:45-54
Stothert Jr, J C; Basadre, J O; Gbaanador, G B et al. (1992) Bronchial blood flow during changes in inhaled oxygen and carbon dioxide concentrations in conscious sheep. Circ Shock 36:120-6
Renzi, P M; Flynn, J T (1992) Endotoxin enhances arachidonic acid metabolism by cultured rabbit microvascular endothelial cells. Am J Physiol 263:H1213-21
Flynn, J T; Hellerman, P; Shelly, M A (1990) Zymosan-activated plasma-mediated thromboxane production by the perfused rabbit liver and isolated hepatocytes: involvement of calcium. Prostaglandins 40:383-95
Gee, M H; Tahamont, M V; Flynn, J T et al. (1987) Prostaglandin E1 prevents increased lung microvascular permeability during intravascular complement activation in sheep. Circ Res 61:420-8
Flynn, J T (1987) Inhibition of complement-mediated hepatic thromboxane production by mepacrine, a phospholipase inhibitor. Prostaglandins 33:287-99
Gee, M H; Perkowski, S Z; Tahamont, M V et al. (1986) Thromboxane as a mediator of pulmonary dysfunction during intravascular complement activation in sheep. Am Rev Respir Dis 133:269-73
Gee, M H; Perkowski, S Z; Tahamont, M V et al. (1985) Arachidonate cyclooxygenase metabolites as mediators of complement-initiated lung injury. Fed Proc 44:46-52
Gee, M H; Tahamont, M V; Perkowski, S Z et al. (1985) Arachidonic acid metabolites as mediators of lung injury during intravascular complement activation. Prog Biochem Pharmacol 20:108-19